Dr. Lili Li

Specific Research / Sites of Interest
- Dysregulation of cell signaling drives tumor development via protein post-translational modifications (PTMs)
- Identification of novel regulatory proteins involved in cancer cell stemness and metabolism through PTMs during tumorigenesis
- Development of therapeutic strategies targeting PTMs involved in tumorigenesis
- Crosstalk between cell signaling and epigenetic regulation in EBV-associated carcinomas
Short Biography
Dr Li is currently Research Associate Professor at the Department of Clinical Oncology, the Chinese University of Hong Kong. After her undergraduate and postgraduate training in clinical medicine and cancer research at Xiangya School of Medicine, Central South University, Dr Li completed her postdoctoral training at the Department of Clinical Oncology, CUHK and was appointed as Research Assistant Professor in 2014.Dr Li's research focuses on post-translational modulations of cell signaling dysfunction during tumorigenesis. She has published ~100 papers in international journals (h-index: 46; google scholar), including Cell Death & Differentiation, PNAS, Clinical Cancer Res, Oncogene, and Cell Res. Her research has been supported by funding from RGC, HMRF, ITF and NSFC. She has received the MoE Award for Outstanding Scientific Research in Natural Sciences. She is also an editorial board member of Clinical Epigenetics and Epigenomes.
Most Representative Publications
1. Li L*, Shu XS, Geng H, Ying J, Guo L, Luo J, Xiang T, Wu L, Ma BBY, Chan ATC, Zhu X, Ambinder RF, Tao Q* (*corresp author). A novel tumor suppressor encoded by a 1p36.3 lncRNA functions as a phosphoinositide-binding protein repressing AKT phosphorylation/ activation and promoting autophagy. Cell Death Differ. 2023 Feb 23. doi: 10.1038/s41418-023-01129-w |
2. Ying Y, Wang M, Chen Y, Li M, Ma C, Zhang J, Huang X, Jia M, Zeng J, Wang Y, Li L, Wang X, Tao Q, Shu XS. Zinc finger protein 280C contributes to colorectal tumorigenesis by maintaining epigenetic repression at H3K27me3-marked loci. Proc Natl Acad Sci U S A. 2022 May 1;119(22):e2120633119 |
3. Wong KC, Hui EP, Lo KW, Lam WK, Johnson D, Li L, Tao Q, Chan KC, To KF, King AD, Ma BB, Chan AT. Nasopharyngeal Carcinoma: An Evolving Paradigm. Nature Reviews Clin Oncol. 2021; 18:679-695. |
4. Tao C, Luo J, Tang J, Zhou D, Feng S, Qiu Z, Putti TC, Xiang T, Tao Q, Li L*, Ren G* (*corresp author). The tumor suppressor Zinc finger protein 471 suppresses breast cancer growth and metastasis through inhibiting AKT and Wnt/β-catenin signaling. Clin Epigenetics. 2020 Nov 17; 12(1):173. |
5. Li L*, Fan Y, Huang X, Luo J, Zhong L, Shu XS, Lu L, Xiang T, Chan AT, Yeo W, Chen C, Chan WY, Huganir RL, Tao Q* (corresp author). Tumor suppression of Ras GTPase activating protein RASA5 antagonizing Ras signaling perturbation in human carcinomas. iScience. 2019; 21:1-18. |
6. Li L, Xu J, Qiu G, Ying J, Du Z, Xiang T, Wong KY, Srivastava G, Zhu XF, Mok TS, Chan AT, Chan FK, Ambinder RF, Tao Q. Epigenomic characterization of a p53-regulated 3p22.2 tumor suppressor that inhibits STAT3 phosphorylation via protein docking and is frequently methylated in esophageal and other carcinomas. Theranostics. 2018; 8(1):61-77. |
7. Li L, Zhang Y, Fan Y, Sun K, Su X, Du Z, Tsao SW, Loh TK, Sun H, Chan AT, Zeng YX, Chan WY, Chan FK, Tao Q. Characterization of the nasopharyngeal carcinoma methylome identifies aberrant disruption of key signaling pathways and methylated tumor suppressor genes. Epigenomics. 2015; 7(2):155-73. |
8. Li L, Ying J, Tong X, Zhong L, Su X, Xiang T, Shu X, Rong R, Xiong L, Li H, Chan AT, Ambinder RF, Guo Y, Tao Q. Epigenetic identification of receptor tyrosine kinase-like orphan receptor 2 as a functional tumor suppressor inhibiting β-catenin and AKT signaling but frequently methylated in common carcinomas. Cell Mol Life Sci. 2014; 71(11):2179-92. |
9. Li L, Ying J, Li H, Zhang Y, Shu XS, Fan Y, Tan J, Cao Y, Tsao SW, Srivastava G, Chan AT, Tao Q. The human cadherin 11 is a pro-apoptotic tumor suppressor modulating cell stemness through WNT/β-catenin signaling and silenced in common carcinomas. Oncogene. 2012; 31(34):3901-12. |
10. Li L, Tao Q*, Jin H, van Hasselt A, Poon FF, Wang X, Zeng MS, Jia WH, Zeng YX, Chan AT*, Cao Y* (*corresp author). The tumor suppressor UCHL1 forms a complex with p53/MDM2/ARF to promote p53 signaling and is frequently silenced in nasopharyngeal carcinoma. Clin Cancer Res. 2010; 16(11):2949-58. |